SuperworthLifevantage profit margin LFVN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 2.8%
- Operating margin, 12 months
- 3.3%
- Net margin on a year earlier
- −1.5 pts
- Peer median
- 15.7%
Over the twelve months to Jun 30, 2026, Lifevantage kept 2.8% of its revenue as net profit, with an operating margin of 3.3% and a gross margin of 77.6%.
Five years earlier its net margin was 5.9%.
The median for 8 large drugmakers of a similar size is 15.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | 2.8% | 3.3% | 77.6% |
| FY2025 | 4.3% | 5.3% | 80.4% |
| FY2024 | 1.5% | 2.2% | 79.3% |
| FY2023 | 1.2% | 2.0% | 79.7% |
| FY2022 | 1.5% | 3.7% | 81.5% |
| FY2021 | 5.9% | 8.0% | 82.7% |
| FY2020 | 5.0% | 6.6% | 83.7% |
| FY2019 | 3.3% | 4.3% | 83.2% |
| FY2018 | 2.8% | 5.1% | 82.9% |
| FY2017 | 0.8% | 2.2% | 83.2% |
| FY2016 | 3.0% | 6.5% | 83.6% |
| FY2015 | 3.7% | 7.3% | 85.3% |
| FY2014 | 5.3% | 9.1% | 84.5% |
| FY2013 | 3.7% | 5.6% | 82.4% |
| FY2012 | 9.9% | 17.0% | 85.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q4 FY26 | 2.8% | −1.5 pts | 3.3% | |
| Q3 FY26 | 2.9% | −1.2 pts | 3.4% | |
| Q2 FY26 | 3.7% | +0.3 pts | 4.3% | |
| Q1 FY26 | 4.4% | +2.3 pts | 5.2% | |
| Q4 FY25 | 4.3% | +2.8 pts | 5.3% | |
| Q3 FY25 | 4.1% | +2.4 pts | 5.8% | |
| Q2 FY25 | 3.5% | +2.1 pts | 5.1% | |
| Q1 FY25 | 2.1% | +0.9 pts | 3.1% | |
| Q4 FY24 | 1.5% | +0.3 pts | 2.2% | |
| Q3 FY24 | 1.8% | +2.2 pts | 2.0% | |
| Q2 FY24 | 1.4% | +1.8 pts | 1.7% | |
| Q1 FY24 | 1.2% | +1.0 pts | 1.7% |
Against its peers
Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first, today.
| Company | Profit margin |
|---|---|
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| ATNMActinium Pharmaceuticals | n/m |
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| Peer median | 15.7% |
Where Lifevantage ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Lifevantage
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.